Results 251 to 260 of about 939,495 (280)

Molecular Mechanisms Underlying Oncogenic RET Fusion in Lung Adenocarcinoma [PDF]

Journal of Thoracic Oncology, 2014
Background:Oncogenic RET fusion, caused by an inversion in chromosome 10, was recently identified as a driver mutation for the development of lung adenocarcinoma (LADC).
Takashi Kohno, Mamoru Kato, Hideaki Ogiwara   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

RET fusion in the firing line

Nature Medicine, 2021
Selective RET inhibition shows promising anti-tumor activity in patients with RET fusion–positive NSCLC. Selective RET inhibition shows promising anti-tumor activity in patients with RET fusion–positive NSCLC.
openaire   +1 more source

RET, ROS1 and ALK fusions in lung cancer

Nature Medicine, 2012
Through an integrated molecular- and histopathology-based screening system, we performed a screening for fusions of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1, receptor tyrosine kinase (ROS1) in 1,529 lung cancers and identified 44 ALK-fusion-positive and 13 ROS1-fusion-positive adenocarcinomas, including for unidentified fusion partners for
Kengo, Takeuchi, Manabu, Soda, Yuki, Togashi, Ritsuro, Suzuki, Seiji, Sakata, Satoko, Hatano, Reimi, Asaka, Wakako, Hamanaka, Hironori, Ninomiya, Hirofumi, Uehara, Young, Lim Choi, Yukitoshi, Satoh, Sakae, Okumura, Ken, Nakagawa, Hiroyuki, Mano, Yuichi, Ishikawa   +15 more
openaire   +2 more sources

ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma

Cancer Genetics, 2019
Rearrangements of RET are drivers of oncogenesis, traceable in different cancer types as papillary thyroid carcinoma (PTC), non-small cell lung cancer, colorectal or breast cancer. Anchored multiplex PCR based next-generation sequencing (NGS) can detect RET rearrangements involving previously unknown partner genes.A sample of PTC underwent NGS ...
Julia Isabelle, Staubitz, Thomas Johannes, Musholt, Arno, Schad, Erik, Springer, Hauke, Lang, Krishnaraj, Rajalingam, Wilfried, Roth, Nils, Hartmann   +7 more
openaire   +2 more sources

A Novel Oncogenic RET Fusion Variant in NSCLC: RELCH-RET

Journal of Thoracic Oncology, 2021
openaire   +2 more sources

RET-Inhibition beim RET-Fusions-positiven NSCLC

Im Fokus Onkologie, 2021
openaire   +1 more source

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial☆

Annals of Oncology, 2022
S Kong, J F Gainor, A S Mansfield
exaly  

Selective Targeting of RET Fusions in Lung Cancer

Journal of Clinical Oncology, 2023
Jessica J. Lin, Justin F. Gainor
openaire   +2 more sources

RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Journal of Thoracic Oncology, 2023
Mihaela Aldea, Anas Gazzah, Jordi Remon Masip   +2 more
exaly  

Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing

Cancer Science, 2022
Dezhi Cheng, Tonghui Ma, Weiran Wang
exaly